Literature DB >> 2543016

Platelet alpha-2-receptor binding and adenylate cyclase activity in panic disorder.

D S Charney1, R B Innis, R S Duman, S W Woods, G R Heninger.   

Abstract

The function of the alpha-2-receptor and intracellular effector systems was examined in 39 panic disorder patients and 30 healthy subjects using the platelet as a model system. Alpha-2-receptor density, as reflected by 3H-yohimbine binding, was not different between the two groups. Platelet alpha-2-receptor affinity was decreased (higher Kd) in the panic disorder patients. Other significant abnormalities in the patients included a decreased basal adenylate cyclase activity, reduced EC50 for the epinephrine inhibition of adenylate cyclase activity, and decreased stimulation of adenylate cyclase activity by prostaglandin E1 and sodium fluoride. These results are consistent with a dysfunction in some panic disorder patients at the level of the stimulatory GTP binding regulatory protein, Gs, or the adenylate cyclase catalytic unit. The relationship of these findings to previous studies of noradrenergic function in panic disorder patients is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2543016     DOI: 10.1007/bf00442014

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

Review 1.  Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety.

Authors:  D E Redmond; Y H Huang
Journal:  Life Sci       Date:  1979-12-24       Impact factor: 5.037

2.  Reduced cyclic AMP production in the blood platelets from schizophrenic patients.

Authors:  M S Kafka; D P van Kammen; W E Bunney
Journal:  Am J Psychiatry       Date:  1979-05       Impact factor: 18.112

3.  Prostaglandin receptor sensitivity in psychiatric disorders.

Authors:  P D Kanof; C Johns; M Davidson; L J Siever; E F Coccaro; K L Davis
Journal:  Arch Gen Psychiatry       Date:  1986-10

4.  alpha 2-Adrenergic receptor sensitivity in depression. The plasma MHPG, behavioral, and cardiovascular responses to yohimbine.

Authors:  G R Heninger; D S Charney; L H Price
Journal:  Arch Gen Psychiatry       Date:  1988-08

5.  Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder.

Authors:  D S Charney; S W Woods; G R Heninger
Journal:  Psychiatry Res       Date:  1989-02       Impact factor: 3.222

6.  Variations in circulating catecholamines fail to alter human platelet alpha-2-adrenergic receptor number or affinity for [3H]yohimbine or [3H]dihydroergocryptine.

Authors:  M A Pfeifer; K Ward; T Malpass; J Stratton; J Halter; M Evans; H Beiter; L A Harker; D Porte
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

7.  Aluminum: a requirement for activation of the regulatory component of adenylate cyclase by fluoride.

Authors:  P C Sternweis; A G Gilman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Noradrenergic function in schizophrenia.

Authors:  W M Glazer; D S Charney; G R Heninger
Journal:  Arch Gen Psychiatry       Date:  1987-10

9.  Platelet alpha-adrenergic binding and biochemical responsiveness in depressed patients and controls.

Authors:  L J Siever; M S Kafka; S Targum; C R Lake
Journal:  Psychiatry Res       Date:  1984-04       Impact factor: 3.222

10.  Postsynaptic supersensitivity in schizophrenia.

Authors:  G N Pandey; D L Garver; C Tamminga; S Ericksen; S I Ali; J M Davis
Journal:  Am J Psychiatry       Date:  1977-05       Impact factor: 18.112

View more
  2 in total

1.  Anxiety and cardiovascular risk: Review of Epidemiological and Clinical Evidence.

Authors:  O Olafiranye; G Jean-Louis; F Zizi; J Nunes; Mt Vincent
Journal:  Mind Brain       Date:  2011-08

2.  Platelet adenylate cyclase activity in Israeli victims of Iraqi Scud missile attacks with post-traumatic stress disorder.

Authors:  R Weizmann; E Gur; N Laor; A Reiss; U Muller; A Yoresh; B Lerer; M E Newman
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.